The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review.

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 DOI:10.1080/21645515.2023.2212568

Aparajita Sarkar, Sara Omar, Aya Alshareef, Kareem Fanous, Shaunak Sarker, Hasan Alroobi, Fahad Zamir, Mahmoud Yousef, Dalia Zakaria

{"title":"The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review.","authors":"Aparajita Sarkar, Sara Omar, Aya Alshareef, Kareem Fanous, Shaunak Sarker, Hasan Alroobi, Fahad Zamir, Mahmoud Yousef, Dalia Zakaria","doi":"10.1080/21645515.2023.2212568","DOIUrl":null,"url":null,"abstract":"<p><p>The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high transmissibility, immune evasion, and reduced severity when compared to the earlier variants. The lesser vaccine effectiveness against Omicron and its reduced severity created vaccination hesitancy among the public. This review compiled data reporting the relative prevalence of Omicron as compared to the early variants to give an insight into the existing variants, which may shape the decisions regarding the targets of the newly developed vaccines. Complied data revealed more than 90% prevalence within the infected cohorts in some countries. The BA.1 subvariant predominated over the BA.2 during the early stages of the Omicron wave. Moreover, BA.4/BA.5 subvariants were detected in South Africa, USA and Italy between October 2021 and April 2022. It is therefore important to develop vaccines that protect against Omicron as well as the early variants, which are known to cause more severe complications.</p>","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2212568"},"PeriodicalIF":4.8000,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d4/ec/KHVI_19_2212568.PMC10234134.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21645515.2023.2212568","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high transmissibility, immune evasion, and reduced severity when compared to the earlier variants. The lesser vaccine effectiveness against Omicron and its reduced severity created vaccination hesitancy among the public. This review compiled data reporting the relative prevalence of Omicron as compared to the early variants to give an insight into the existing variants, which may shape the decisions regarding the targets of the newly developed vaccines. Complied data revealed more than 90% prevalence within the infected cohorts in some countries. The BA.1 subvariant predominated over the BA.2 during the early stages of the Omicron wave. Moreover, BA.4/BA.5 subvariants were detected in South Africa, USA and Italy between October 2021 and April 2022. It is therefore important to develop vaccines that protect against Omicron as well as the early variants, which are known to cause more severe complications.

Abstract Image

查看原文本刊更多论文

不同国家SARS-CoV-2感染人群中基因组变体的相对流行率:一项系统综述

2021年10月检测到严重急性呼吸系统综合征冠状病毒2型的奥密克戎变异株，与早期变异株相比，该变异株表现出高传播性、免疫逃避和严重程度降低。疫苗对奥密克戎的有效性较低，严重程度降低，导致公众对疫苗接种犹豫不决。这篇综述汇编了报告奥密克戎与早期变种相比的相对流行率的数据，以深入了解现有变种，这可能会影响有关新开发疫苗靶点的决策。复杂的数据显示，在一些国家，感染人群中的患病率超过90%。在奥密克戎波的早期阶段，BA.1亚变体占主导地位。此外，在2021年10月至2022年4月期间，在南非、美国和意大利检测到BA.4/BA.5亚变体。因此，开发预防奥密克戎和早期变种的疫苗很重要，众所周知，早期变种会导致更严重的并发症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

自引率

8.30%

发文量

审稿时长

1 months

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.